Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)

References

• Caroscio J. T., Mulvihill M. N., Sterling R., Abrams B. Amyotrophic lateral sclerosis: its natural history. Neurol Clin 1987; 5: 1–8
   PubMed Web of Science ®Google Scholar
• Braun S. R. Respiratory system in amyotrophic lateral sclerosis. Neurol Clin 1987; 5: 9–31
   PubMed Web of Science ®Google Scholar
• Bensimon G., Lacomblez L., Meininger V., ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• Lacomblez L., Bensimon G., Leigh P. N., Guillet P., Meininger V., ALS/Riluzole Study Group. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• Miller R. G., Mitchell J. D., Lyon M., Moore D. H. Riluzole for amyotrophoc lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 191–206
   PubMed Web of Science ®Google Scholar
• Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62
   PubMed Web of Science ®Google Scholar
• Beal M. F., Ferrante R. J., Browne S. E., Matthews R. T., Kowall N. W., Brown R. H., Jr. Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 646–54
   Web of Science ®Google Scholar
• Ferrante R. J., Browne S. E., Shinobu L. A., Bowling A. C., Baik M. J., MacGarvey U., et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064–74
   PubMed Web of Science ®Google Scholar
• Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase‐1 mutation. Neuropathology 2001; 21: 82–92
   PubMed Web of Science ®Google Scholar
• Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI‐186), on acute brain infarction. Cerebrovascular Dis 2003; 15: 222–9
   PubMed Web of Science ®Google Scholar
• Watanabe T., Yuki S., Egawa M., Nishi H. Protective effects of MCI‐186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994; 268: 1597–1604
   PubMed Web of Science ®Google Scholar
• Mizuno A., Umemura K., Nakashima M. Inhibitory effect of MCI‐186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol 1998; 30: 575–8
   PubMedGoogle Scholar
• Yamamoto T., Yuki S., Watanabe T., Mituka M., Saito K., Kogure K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Research 1997; 762: 240–2
   PubMed Web of Science ®Google Scholar
• Ikeda K., Iwasaki Y., Kinoshita M. Treatment of wobbler mice with free radical scavenger. Molecular mechanism and therapeutics of amyotrophic lateral sclerosis. Elsevier Science B.V 2001; 335–40
   Google Scholar
• Cedarbaum J. M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13–21
   PubMed Web of Science ®Google Scholar
• Acworth I. N., Bogdanov M. B., Mccabe D. R., Beal M. F. Estimation of hydroxyl free radical levels in vivo based on liquid chromatography with electrochemical detection. Methods Enzymol 1999; 300: 297–313
   PubMed Web of Science ®Google Scholar
• Florence J., Brinkmann J., Szirony K., Sanjak M., Brooks B., Pestronk A., et al. Implementation of evaluation procedures in a multicenter study of treatment in ALS: ensuring reliability. Muscle Nerve 1994; 1((Suppl))S166
   Google Scholar
• ALS CNTF Treatment Study (ACTS) Phase I–II Study Group. The amyotrophic lateral sclerosis functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996; 53: 141–7
   PubMedGoogle Scholar
• BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999; 52: 1427–33
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study (ACTS) Group. A double‐blind, placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46: 1244–9
   PubMed Web of Science ®Google Scholar
• Oda E., Ohashi Y., Tashiro K., Mizuno Y., Kowa H., Yanagisawa N. Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. Brain and Nerve 1996; 48: 999–1007
   PubMedGoogle Scholar
• Ohasi Y., Tashiro K., Itoyama Y., Nakano I., Sobue G., Nakamura S., et al. Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS‐R)Japanese version. Brain and Nerve 2001; 53: 346–55
   PubMedGoogle Scholar
• Abe K., Pan L. H., Watanabe M., Kato T., Itoyama Y. Induction of nitrotyrosine‐like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 1995; 199: 152–4
   PubMed Web of Science ®Google Scholar
• Sasaki S., Shibata N., Komori T., Iwata M. iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci Lett 2000; 291: 44–8
   PubMed Web of Science ®Google Scholar
• Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. Remarkable increase in cerebrospinal fluid 3‐nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1999; 46: 129–31
   PubMed Web of Science ®Google Scholar
• Bruijn L. I., Beal M. F., Becher M. W., Schulz J. B., Wong P. C., Price D. L., et al. Elevated free nitrotyrosine levels, but not protein‐bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)‐like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS‐linked superoxide dismutase 1 mutant. Proc Natl Acad. Sci. USA 1997; 94: 7606–11
   PubMed Web of Science ®Google Scholar